TriSalus Life Sciences (NASDAQ:TLSI) Upgraded to “Strong-Buy” at Roth Capital

Roth Capital upgraded shares of TriSalus Life Sciences (NASDAQ:TLSI) to a strong-buy rating in a research report report published on Monday,Zacks.com reports. Roth Capital also issued estimates for TriSalus Life Sciences’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.47) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.19) EPS.

Several other analysts also recently commented on TLSI. Roth Mkm initiated coverage on shares of TriSalus Life Sciences in a research report on Monday. They set a “buy” rating and a $11.00 price objective on the stock. Northland Securities initiated coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 price objective for the company. Northland Capmk upgraded TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Finally, Oppenheimer began coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They issued an “outperform” rating and a $10.00 price target for the company. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $12.25.

TriSalus Life Sciences Stock Down 10.9 %

Shares of TLSI opened at $4.01 on Monday. The business has a 50-day simple moving average of $4.38 and a two-hundred day simple moving average of $5.85. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $10.42. The stock has a market cap of $122.26 million, a price-to-earnings ratio of -1.80 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $7.36 million for the quarter. On average, equities analysts anticipate that TriSalus Life Sciences will post -1.5 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Mary T. Szela purchased 7,520 shares of the business’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the acquisition, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This represents a 2.03 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 32.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Walleye Capital LLC purchased a new stake in TriSalus Life Sciences during the third quarter valued at $66,000. MSD Partners L.P. purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at about $184,000. Wolverine Asset Management LLC bought a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at about $240,000. Highbridge Capital Management LLC purchased a new position in TriSalus Life Sciences in the second quarter worth about $1,184,000. Finally, Duquesne Family Office LLC increased its stake in TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after acquiring an additional 110,966 shares during the last quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.